PRRT2 and colorectal carcinoma: Apart from one CRC-SC line, where the efficacy barely reached the −1.5 x SD threshold, Tyrphostin-9, a PDGFR inhibitor and Rottlerin, another PKC inhibitor that is more active on the δ iso-enzyme, were among the most effective drugs tested.